profit from every $100 of sales.
$0$100
TELA Bio
$0.94+17.72% today
-20.9% in 1 year
1-year low $0.561-year high $1.41
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What TELA Bio sold, what it kept, and what it did with the cash.
Sales went from $41.4 million in 2022 to $80.3 million in 2025, with -$38.8 million of profit last year.
SalesProfit
TELA Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| TELA Bio | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads TELA Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 41 | 58 | 69 | 80 | |
| 27 | 40 | 46 | 54 | |
| -39 | -44 | -42 | -34 | |
| -39 | -41 | -32 | -32 | |
| -44 | -47 | -38 | -39 | |
| -2.72 | -2.04 | -1.33 | -0.83 | |
| 65.3% | 68.6% | 67.1% | 67.7% | |
| -94.2% | -75.4% | -60.2% | -42.0% | |
| -106.9% | -79.8% | -54.6% | -48.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 68 | 78 | 87 | 81 |
| Cash | 42 | 47 | 53 | 51 |
| Total debt | 40 | 41 | 42 | 56 |
| Total liabilities | 54 | 59 | 58 | 75 |
| 14 | 19 | 28 | 6 | |
| 16 | 23 | 29 | 47 | |
| -58.3% | -54.6% | -36.8% | -42.2% | |
| -309.7% | -247.1% | -133.0% | -615.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -41 | -41 | -42 | -28 | |
| 2 | 1 | 1 | 0 | |
| -43 | -41 | -43 | -29 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 5 | 4 | 4 |
Valuation
- –
- –
- –
- -10.9×
- 0.5×
- –
- –
- -67.4%
- -91.3%
- 0.0%
Profitability
- 67.7%
- -42.0%
- -48.4%
- -40.5%
- -64.9%
- -67.0%
- -1,344.5%
- -57.0%
- -64.9%
- 11.2%
Growth
- +24.7%
- –
- +32.7%
- –
- +34.2%
Financial health
- –
- -10.74
- 79.9%
- -17.1×
- 3.61
- 2.92
- 1.16
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 958
Bottom 7%of 889
Top 22%of 890
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.21 | -0.14 | −50.0% |
| Mar 25, 2026 | -0.16 | -0.18 | +11.1% |
| Nov 13, 2025 | -0.19 | -0.17 | −11.8% |
| Aug 11, 2025 | -0.22 | -0.18 | −22.2% |
| May 8, 2025 | -0.25 | -0.21 | −19.0% |
| Mar 20, 2025 | -0.23 | -0.24 | +4.2% |
| Nov 7, 2024 | -0.42 | -0.37 | −13.5% |
| Aug 12, 2024 | -0.51 | -0.45 | −13.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
43No pass
Philip Fisher
45No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
38No pass
Questions about TELA Bio
Is TELA Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the TELA Bio AI analysis
What does TELA Bio do?
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It is in Medical - Devices.
Does TELA Bio pay a dividend?
No. TELA Bio does not pay a dividend at the moment.
Is TELA Bio stock halal?
No. TELA Bio does not pass our halal screen: its debt is 132% of its market value, at or above the 33% limit. How we check
How has TELA Bio stock done over the past year?
Down 20.9% over the past twelve months, to $0.94. It traded between $0.56 and $1.41 and is 33.2% below its high.
Who are TELA Bio's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with TELA Bio's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.